Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 460

1.

Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013.

Sagara Y, Freedman RA, Wong SM, Aydogan F, Nguyen A, Barry WT, Golshan M.

Breast Cancer Res Treat. 2017 Aug 3. doi: 10.1007/s10549-017-4436-9. [Epub ahead of print]

PMID:
28776282
2.

Patient experience with breast reconstruction process following bilateral mastectomy in BRCA mutation carriers.

Nurudeen S, Guo H, Chun Y, Coopey S, Barry W, Garber J, Dominici LS.

Am J Surg. 2017 Jun 28. pii: S0002-9610(17)30316-1. doi: 10.1016/j.amjsurg.2017.06.017. [Epub ahead of print]

PMID:
28683895
3.

Trial designs and results supporting treatment de-escalation and escalation.

Regan MM, Barry WT.

Breast. 2017 Jun 30. pii: S0960-9776(17)30492-7. doi: 10.1016/j.breast.2017.06.020. [Epub ahead of print]

PMID:
28673539
4.

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).

Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV.

AAPS J. 2017 Jun 15. doi: 10.1208/s12248-017-0101-9. [Epub ahead of print]

PMID:
28620884
5.

An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.

Hill KE, Kelly AD, Kuijjer ML, Barry W, Rattani A, Garbutt CC, Kissick H, Janeway K, Perez-Atayde A, Goldsmith J, Gebhardt MC, Arredouani MS, Cote G, Hornicek F, Choy E, Duan Z, Quackenbush J, Haibe-Kains B, Spentzos D.

J Hematol Oncol. 2017 May 15;10(1):107. doi: 10.1186/s13045-017-0465-4.

6.

Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ.

Wong SM, King T, Boileau JF, Barry WT, Golshan M.

Ann Surg Oncol. 2017 Sep;24(9):2509-2517. doi: 10.1245/s10434-017-5867-6. Epub 2017 Apr 28.

PMID:
28455673
7.

Epidemiology and trends in the antibiotic susceptibilities of Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region, 2010-2013.

Chang YT, Coombs G, Ling T, Balaji V, Rodrigues C, Mikamo H, Kim MJ, Rajasekaram DG, Mendoza M, Tan TY, Kiratisin P, Ni Y, Barry W, Xu Y, Chen YH, Hsueh PR.

Int J Antimicrob Agents. 2017 Jun;49(6):734-739. doi: 10.1016/j.ijantimicag.2017.01.030. Epub 2017 Apr 20.

PMID:
28435019
8.

Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance).

Mandelblatt JS, Cai L, Luta G, Kimmick G, Clapp J, Isaacs C, Pitcher B, Barry W, Winer E, Sugarman S, Hudis C, Muss H, Cohen HJ, Hurria A.

Breast Cancer Res Treat. 2017 Jul;164(1):107-117. doi: 10.1007/s10549-017-4222-8. Epub 2017 Mar 31.

PMID:
28364214
9.

Pediatric Morgagni diaphragmatic hernia: a descriptive study.

Golden J, Barry WE, Jang G, Nguyen N, Bliss D.

Pediatr Surg Int. 2017 Jul;33(7):771-775. doi: 10.1007/s00383-017-4078-3. Epub 2017 Mar 13.

PMID:
28289880
10.

Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.

Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I.

J Natl Compr Canc Netw. 2017 Mar;15(3):316-324.

PMID:
28275032
11.

Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study.

Vaz-Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA.

Oncologist. 2017 Apr;22(4):386-393. doi: 10.1634/theoncologist.2016-0369. Epub 2017 Feb 27.

PMID:
28242790
12.

Bayesian response-adaptive designs for basket trials.

Ventz S, Barry WT, Parmigiani G, Trippa L.

Biometrics. 2017 Feb 17. doi: 10.1111/biom.12668. [Epub ahead of print]

PMID:
28211944
13.

Local and Global Cues in the Prosodic Realization of Broad and Narrow Focus in Bulgarian.

Andreeva B, Barry WJ, Koreman J.

Phonetica. 2016;73(3-4):256-278. doi: 10.1159/000448044. Epub 2017 Feb 23.

PMID:
28208148
14.

Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer.

Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M.

Ann Surg. 2017 Mar;265(3):581-589. doi: 10.1097/SLA.0000000000001698.

PMID:
28169929
15.

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.

Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E.

Ann Oncol. 2017 Mar 1;28(3):512-518. doi: 10.1093/annonc/mdw672.

PMID:
27993796
16.

Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Kelley MJ, Jha G, Shoemaker D, Herndon JE 2nd, Gu L, Barry WT, Crawford J, Ready N.

Cancer Invest. 2017 Jan 2;35(1):32-35. doi: 10.1080/07357907.2016.1253710. Epub 2016 Dec 2.

PMID:
27911119
17.

Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model.

Masko EM, Alfaqih MA, Solomon KR, Barry WT, Newgard CB, Muehlbauer MJ, Valilis NA, Phillips TE, Poulton SH, Freedland AR, Sun S, Dambal SK, Sanders SE, Macias E, Freeman MR, Dewhirst MW, Pizzo SV, Freedland SJ.

Prostate. 2017 Apr;77(5):446-457. doi: 10.1002/pros.23282. Epub 2016 Nov 30.

PMID:
27900797
18.

TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.

Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, Zhao J, De Tribolet-Hardy J, Guarducci C, Bonechi M, Laing N, Winer EP, Brown M, Leo AD, Malorni L.

Clin Cancer Res. 2016 Dec 1;22(23):5755-5764. Epub 2016 May 16.

PMID:
27185372
19.

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.

Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG.

Oncologist. 2017 Jan;22(1):25-32. doi: 10.1634/theoncologist.2016-0229. Epub 2016 Oct 27.

PMID:
27789775
20.

Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.

Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, Winer EP, Freedman RA.

Breast Cancer Res Treat. 2016 Aug;159(1):151-62. doi: 10.1007/s10549-016-3927-4. Epub 2016 Aug 2.

PMID:
27484879

Supplemental Content

Support Center